New Phase 2 REC-4881 data presented at CGA-IGC show profound and durable polyp burden reduction in FAP, with activity throughout the gastrointestinal tract and in larger, higher-risk polyps.
New Phase 2 REC-4881 data presented at CGA-IGC show profound and durable polyp burden reduction in FAP, with activity throughout the gastrointestinal tract and in larger, higher-risk polyps.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in